Want to see JP:4582 full AI Analyst Report?
Top Page
Symbio Pharmaceuticals Limited
(4582)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥61.00
▼(-10.29% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily weighed down by deteriorating financial performance, including multi-year revenue declines, sustained losses, heavy cash burn, and increased leverage with shrinking equity. Technicals are only mildly supportive in the short term (price near short moving averages and neutral RSI) but remain weak on a longer-term basis (below 100/200DMAs and negative MACD). Valuation is difficult to assess due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Strong Gross Margin
A consistently strong gross margin indicates the products retain pricing or production economics that can support recovery. However, realizing this benefit depends on reducing selling, R&D, and other operating costs.
Negative Factors
Sustained Revenue Decline
Multi-year revenue contraction signals weakening commercial momentum and reduces the scale available to absorb fixed development and selling costs. Continued declines could limit investment capacity and make a return to profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margin
A consistently strong gross margin indicates the products retain pricing or production economics that can support recovery. However, realizing this benefit depends on reducing selling, R&D, and other operating costs.
Read all positive factors
Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.97B
Dividend YieldN/A
Average Volume (3M)577.10K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-37.69%
EPS Growth1.85%
CountryJP
Employees91
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-100.06
Shares Outstanding80,246,460
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Symbio Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood canc...
How the Company Makes Money
Symbio Pharmaceuticals makes money primarily through (1) sales of its pharmaceutical products in markets where it holds commercialization rights, typically generating revenue when products are shipped to wholesalers, medical institutions, or distr...
Symbio Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13B | 1.31B | 2.45B | 5.59B | 10.01B | 8.25B |
| Gross Profit | 791.92M | 947.34M | 1.87B | 4.41B | 7.60B | 5.80B |
| EBITDA | -5.99B | -4.60B | -3.78B | -714.00M | 2.06B | 1.11B |
| Net Income | -6.03B | -4.78B | -3.83B | -1.96B | 1.18B | 2.03B |
Balance Sheet | ||||||
| Total Assets | 1.91B | 3.87B | 4.97B | 8.17B | 17.43B | 15.18B |
| Cash, Cash Equivalents and Short-Term Investments | 977.18M | 2.88B | 3.96B | 6.52B | 6.28B | 3.86B |
| Total Debt | 832.50M | 1.98B | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.49B | 2.60B | 770.77M | 8.14B | 8.92B | 8.43B |
| Stockholders Equity | -582.85M | 1.27B | 4.20B | 7.21B | 8.51B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -4.58B | -3.44B | -427.48M | 1.57B | 76.20M |
| Operating Cash Flow | 0.00 | -4.58B | -3.42B | -194.69M | 1.61B | 140.04M |
| Investing Cash Flow | 0.00 | -75.92M | -3.96M | -376.70M | -47.13M | -70.85M |
| Financing Cash Flow | 0.00 | 3.62B | 708.47M | 680.16M | 627.99M | -71.92M |
Symbio Pharmaceuticals Limited Technical Analysis
Negative
68.00
Price Trends
69.32
Negative
78.68
Negative
92.43
Negative
Market Momentum
-1.86
Positive
32.64
Neutral
12.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 68 is below the 20-day moving average (MA) of 68.05, below the 50-day MA of 69.32, and below the 200-day MA of 92.43, indicating a bearish trend. The MACD of -1.86 indicates Positive momentum. The RSI at 32.64 is Neutral, neither overbought nor oversold. The STOCH value of 12.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.
Symbio Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥13.52B | 19.58 | ― | ― | 13.30% | 66.38% | |
59 Neutral | ¥10.62B | 31.54 | ― | 1.06% | 25.89% | ― | |
54 Neutral | ¥5.70B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥7.92B | -8.71 | -54.56% | ― | 32.42% | 61.00% | |
44 Neutral | ¥4.97B | -0.62 | ― | ― | -37.69% | 1.85% | |
40 Underperform | ¥4.47B | -4.64 | ― | ― | 167.44% | 49.38% |
* Healthcare Sector Average
JP:4582
Symbio Pharmaceuticals Limited
62.00
-86.00
-58.11%
JP:4597
Solasia Pharma KK
29.00
-8.00
-21.62%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
311.00
5.57
1.82%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4574
Taiko Pharmaceutical Co., Ltd.
268.00
-37.00
-12.13%
JP:4586
Medrx Co., Ltd.
66.00
-45.00
-40.54%
Symbio Pharmaceuticals Limited Corporate Events
SymBio’s First-Half Loss Deepens as Equity Turns Negative
Aug 10, 2026
SymBio Pharmaceuticals reported a sharp decline in first-half 2026 net sales to ¥469 million, down 27.3% year on year, alongside a wider operating loss of ¥3.64 billion as the company remained in a loss-making phase. The firm’s fin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.